Advances in Predictive Research of Immune Checkpoint Inhibitors-related
Adverse Events.
10.3779/j.issn.1009-3419.2023.106.20
- Author:
Jing ZHANG
1
;
Xueqin CHEN
1
;
Shenglin MA
2
Author Information
1. Fourth Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou 310053, China.
2. Department of Thoracic
Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
- Publication Type:Journal Article
- Keywords:
Biomarkers;
Clinical factors;
Immune checkpoint inhibitors;
Immune-related adverse events
- MeSH:
Humans;
Immune Checkpoint Inhibitors/adverse effects*;
Lung Neoplasms/drug therapy*;
Neoplasms/pathology*;
Immunotherapy/adverse effects*
- From:
Chinese Journal of Lung Cancer
2023;26(10):789-794
- CountryChina
- Language:Chinese
-
Abstract:
The era of tumor treatment has been revolutionized by the advent of immune checkpoint inhibitors. However, while immunotherapy benefits patients, it can also lead to immune-related adverse events that may affect multiple organs and systems throughout the body, potentially even posing a life-threatening risk. The diverse clinical manifestations and onset times of these adverse events further complicate their prediction and diagnosis. The purpose of this paper is to review the clinical characteristics and predicted biomarkers of adverse events related to inhibitors at immune checkpoints, in order to help clinicians evaluate drug risks and early warn adverse events.
.
